MASLD and Liver Cancer: What’s the Link? Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where too much fat builds up in your liver. Unlike fatty liver caused by ...
News Medical on MSN16d
New drug approach shows promise in treating metabolic liver diseasesA MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental ...
The disease spans from benign fat accumulation in the liver (steatosis) to its more severe form, metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH).
Endoscopic sleeve gastroplasty combined with lifestyle changes was more effective for weight loss in patients with MASH and obesity than lifestyle changes alone.
Galectin's MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people with liver scarring. Since the biotech shared ...
The topline results from the ESSENCE trial of semaglutide showed that a once-weekly 2.4mg dose of the drug was better than placebo at resolving MASH and improving liver fibrosis, meeting its ...
MASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant ...
Dr. Lawitz shared the complete details of the 16-week, randomized, placebo-controlled, multi-center Phase 2 study of FXR314 in MASH patients ... reduction in liver fat content from baseline ...
The disease spans from benign fat accumulation in the liver (steatosis) to its more severe form, metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback